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economic status (SES) is a robust predictor of medication nonadher-
ence, the strength of this association remains unclear. Objectives:
1) To estimate the proportion of studies that identiﬁed SES as a
potential risk indicator of nonadherence, 2) to describe the type of SES
measurements, and 3) to quantify the association between SES and
nonadherence to antihypertensive pharmacotherapy. Methods: A
systematic review and meta-analysis research design was used. We
searched multiple electronic databases for studies in English or
French examining nonadherence to antihypertensive medications
measured by electronic prescription databases where explanatory
factors were considered. Two authors independently assessed quality,
described the SES measure(s), and recorded its association with
nonadherence to antihypertensives. A random-effects model meta-
analysis was performed, and heterogeneity was examined by using
the I2 statistic. Results: Fifty-six studies with 4,780,293 subjects met
the inclusion criteria. Twenty-four of these studies (43%) did not
report any SES measures. When it was reported (n ¼ 32), only sevensee front matter Copyright & 2014, International S
r Inc.
1016/j.jval.2013.11.011
rn@usask.ca.
ondence to: David F. Blackburn, College of Pharma
ada S7N 5C9.(13%) examined more than one component but none performed a
multidimensional assessment. Most of the studies relied on income or
income-related measures (such as prescription-drug beneﬁts or co-
payments) (27 of 32 [84%]). Meta-analysis could be quantiﬁed in 40
cohorts reported in 30 studies. Overall, the pooled adjusted risk estimate
for nonadherence according to SES (high vs. low) was 0.89 (95%
conﬁdence interval 0.87–0.92; I2 ¼ 95%; Po 0.001). Similar patterns were
observed in all subgroups examined. Conclusions: Published studies
have not found a strong association between low SES and nonadherence
to antihypertensive medications. However, important limitations in the
assessment of SES can be identiﬁed in virtually all studies. Future
studies are required to ascertain whether a stronger association is
observed when SES is determined by comprehensive measures.
Keywords: antihypertensive medications, drug adherence, pharmacy,
population-level, socioeconomic status.
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Socioeconomic status (SES) is a multidimensional construct that
represents an individual’s position relative to other people in the
community. It is commonly considered a product of the inter-
action between material and social factors. Material factors
include income, education, and employment, whereas social
factors are usually represented by living arrangements and family
structure [1]. In health care research, low SES has proven to be a
strong predictor of health care utilization, morbidity, and prema-
ture death [2–5]. Nonadherence to chronic medications, such as
antihypertensives (AHTs), can also be determined by low SES [6,7].
SES is an intriguing factor in the search for determinants of
population-level nonadherence to AHTs because of its associations
with economic, social, and education-related factors. Indeed, allthese factors may affect regular medication use [8]. Although the
relationship between SES and nonadherence has been inconsistent
[9], we hypothesized that methodological approaches may have
attenuated an important relationship. Electronic prescription data-
bases are the methods most frequently used for the assessment of
nonadherence [10,11]; however, they often lack important patient-
level information required to describe SES in detail. As a result,
indirect measures of income such as receipt of prescription-drug
beneﬁts through government co-payments are often used as sole
indicators of SES in many studies [12–15], while direct measures of
income from taxation records are rarely used [6]. In addition, studies
generally do not account for SES factors not related to income and
even fewer incorporate multiple SES measurements representing
different dimensions [16,17]. Finally, several population-based studies
can be identiﬁed in which SES factors are absent altogether [18–20].ociety for Pharmacoeconomics and Outcomes Research (ISPOR).
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ence to AHT medications, as well as the approaches used to acco-
unt for it, we conducted a systematic review and meta-analysis of
the literature pertaining to SES and nonadherence to AHT medi-
cations by using population-based electronic prescription data. Our
study had three objectives: 1) to estimate the proportion of studies
that identiﬁed SES as a potential risk indicator of nonadherence,
2) to describe the type of SES measurements that were used in each
study, and 3) to quantify the association between SES and non-
adherence to AHT medications.Methods
Search Strategy
We used a comprehensive search strategy of electronic databases
including Medline (OVID, 1964 to February 24, 2012), Embase (OVID,
1947 to February 24, 2012), International Pharmaceutical Abstracts
(OVID, 1970 to January 31, 2012), the Cochrane Library (Wiley, 1800
to February 28, 2012), Scopus (Elsevier, from 1823 to February 28,
2012), CINAHL (EBSCO, 1937 to February 28, 2012), PsycINFO (OVID,
1806 to February week 3, 2012), Sociological Abstracts (ProQuest,
1952 to February 28, 2012), ProQuest Dissertations & Theses (1639
to February 28, 2012), Web of Science (Thomson Reuters, 1899 to
February 28, 2012), and OAIster (1975 to Dec 31, 2011). Reference
lists of identiﬁed articles were manually searched for additional
studies not captured in the electronic database reviews.
Study Selection
Studies were included if they satisﬁed the following criteria: 1)
examined nonadherence to AHT medications; 2) used electronic
prescription databases as the source of nonadherence information;
3) conducted multivariable modeling to determine the independent
effect of explanatory covariates on the outcome of nonadherence;
and 4) were published in English or French. Eligible AHT medica-
tions included angiotensin-converting enzyme inhibitors or angio-
tensin receptor blockers, beta-blockers, calcium channel blockers, or
thiazide diuretics for any indication. Studies were not restricted by
design or publication date. In some cases, we contacted authors of
studies to clarify or obtain data.
Review Procedure and Assessment of Methodological Quality
The identiﬁcation of studies was carried out in two steps. First,
after removal of duplicates, two of the authors (M.W.A. and M.L.)
examined the titles and abstracts identiﬁed in the initial search.
Second, the same two reviewers (M.W.A. and M.L.) examined full-
text articles for each study identiﬁed in the ﬁrst step for both
eligibility and methodological quality. Disagreement between the
two reviewers was resolved by additional review and discussion
and then, if required, with tie-breaking by a third reviewer (D.F.
B.). Quality of included studies was assessed by the reviewers (M.
W.A. and M.L.) with a checklist developed by the International
Society for Pharmacoeconomics and Outcome Research (ISPOR)
for retrospective database studies [21,22]. This checklist has been
used in systematic reviews previously [23], and it consists of 27
quality review questions related to data source, research design,
study population, variable deﬁnitions, statistics, and discussion.
From each study, we determined whether a SES measure was
assessed by identifying any material factor (e.g., income, education,
or employment) or social factor (e.g., living alone, or family structure)
that was included in the nonadherence model. In cases in which
these traditional SESmeasures were not used, we identiﬁed ethnicity
as a possible indirect measure in a sensitivity analysis. We also
recorded estimates of the ratio effects measures of nonadherence to
AHT medications along with 95% conﬁdence intervals (95% CIs)corresponding to the measure of SES. In addition, we abstracted
information on region of origin, publication year target medication(s),
adherence measurement (medication possession ratio [MPR]-related
vs. discontinuation-related [11]), number of subjects (total/low SES/
higher SES), follow-up (observation) days, and the number of SES
domains captured in each study. We categorized SES covariates as
income-related and non–income-related and subcategorized income-
related SES covariates as follows: income level, health-plan coverage
or medication co-payment amount, and receipt of social assistance
or income security beneﬁts. Income-level factors were identiﬁed as
direct (e.g., by linking taxation data to dispensation records) or
indirect (e.g., from census neighborhood or coverage type).
Statistical Analysis
We assessed the agreement in study inclusion/exclusion between
reviewers in each step by using Cohen’s kappa statistic (κ) [24]. We
adopted the following interpretations for κ: 0.60 o κ was consid-
ered low agreement, 0.60 r κ r 0.79 was considered good agree-
ment, and κ Z 0.80 was considered very good agreement [25]. We
assessed heterogeneity by using the I2 statistic and the correspond-
ing Tau-squared (τ2) test. This statistic represents the proportion of
variability that can be attributed to between-studies variability [26].
We adopted the following interpretations for the I2 statistic: 0% to
40%, low heterogeneity; 41% to 74%, moderate heterogeneity; and
75% to 100%, considerable heterogeneity. All estimates were pooled
where possible irrespective of the level of heterogeneity observed
and subgroup analyses completed to explore potential sources of
study heterogeneity [27]. We then conducted a random-effects
model meta-analysis by using the inverse-variance method to
estimate the effect of SES on medication nonadherence from the
pooled data [26–28]. A random-effects model accounts for potential
heterogeneity between the populations and unmeasured con-
founding [26]. For studies reporting more than one nonadherence
measure, we prioritized MPR-related outcomes over other meas-
ures. The MPR is calculated usually by summing all days’ supply
during a certain period of observation of the medication and
dividing it by the total days of that period [10]. For studies reporting
more than one SES variable, we used the measure with the largest
effect size regardless of the direction of the association. When
categorical SES measures had more than two levels, we reported
the risk estimate of the highest SES level relative to the lowest.
Subgroup analyses were conducted for type of nonadherence
measurement, type of medication, type of SES measurement, and
region of origin of the data. We used the Z test for overall effects
and the chi-square statistic to test for differences in between-
groups effects [29]. Finally, because ethnicity may be considered
an indirect SES measurement [30,31], we performed sensitivity
analyses by including ethnicity as a measure of SES to assess the
proportion of studies that identiﬁed SES as a potential risk
indicator of nonadherence. In addition, we performed a sensitiv-
ity analysis by using the estimate with the lowest effect size
instead of the highest for studies reporting more than one SES
variable. We evaluated publication bias visually by using the
funnel plot [32]. We adopted the protocol developed by The
Cochrane Collaboration and used Review Manager (Version
5.1.7, Copenhagen: The Nordic Cochrane Centre, The Cochrane
Collaboration, 2011) to perform the meta-analysis [27].Results
Included Studies
Our search identiﬁed 11,351 titles/abstracts, with 56 studies
meeting our inclusion criteria (Fig.1; eTable 1). Overall agreement
for inclusion/exclusion of studies between the reviewers was
Fig. 1 – Flow chart for titles/abstracts and articles included in the review. CI, conﬁdence interval.
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respectively) (Fig. 1). Of these 56 included studies, 8 studies [33–
39] scored less than 50% on the methodological quality review.
The median methodological quality score was 68%, and the
interquartile range was 19%.
Table 1 summarizes the characteristics of included studies.
The total number of subjects included in our review was 4,708,293
(range 236–1,075,285 per study). Most of the studies were con-
ducted in Europe (11 of 56 [20%]) and North America (34 of 56
[61%]). Studies ranged from assessing one AHT medication (6 of
56 [11%]) to assessing combinations of two medications or more.
Nonadherence was measured by discontinuation/nonpersistence
(25 of 56 [45%]), MPR-related measurements (26 of 56 [47%]), or
both (5 of 56 [8%]). The follow-up duration was 180 days or less in
13 studies, 181 days to 365 days in 31 studies, and more than 365
days in 8 studies.
SES Measures
Overall, 24 of 56 studies (43%) did not assess SES with any
material or social measure. When ethnicity was considered asan eligible SES measure, however, the proportion of studies with
no SES measure decreased to 19 of 56 studies (34%). An SES
measure was lacking in all studies published before 2004 (9
studies), compared with 15 of 47 studies (32%) published between
2004 and 2012. Of the 32 studies that assessed SES, 2 studies did
not report estimates of the effect of SES on nonadherence and
could not be obtained from authors [40,41].
No study organized SES variables into multidimensional
scales or indices such as a deprivation index [42,43]. From all
studies that assessed SES, 25 studies (78% [25 of 32]) identiﬁed
only one SES measure among their study subjects. Of these,
prescription-drug coverage or medication co-payment amount
based on income was most commonly used (17 of 25 studies)
[9,15,38,44–57]. Four studies captured the income level [41,58–60],
three studies used social assistance beneﬁts or income security
beneﬁts [61–63], and only one study used the education level
[64].
Seven studies (22% [7 of 32]) identiﬁed more than one SES
measure in their study population. All the studies contained at
least one income-related variable, and three identiﬁed income-
related measures only [36,39,65]. Nonincome variables in the
Table 1 – Characteristics of included studies.
Characteristic Number of
subjects
% of total sample
(n ¼ 4,708,293)
Number of
studies (%)
(N ¼ 56)
Region of data origin
North American 2,666,720 56.6 35 (62.5)
Europe 880,224 18.7 10 (17.9)
Other countries 1,161,349 24.7 11 (19.6)
Date of publication
Before 2004 206,025 4.4 9 (16.1)
2004 and after 4,502,268 95.6 47 (83.9)
AHT medication(s) studied
ACEIs 27,114 0.6 6 (10.7)
ARBs 18,396 0.4 2 (3.6)
BBs 102,690 2.2 6 (10.7)
CCBs 29,324 0.6 2 (3.6)
HCTZ 17,949 0.4 2 (3.6)
Other (if more than one medication was studied) 4,512,820 95.8 38 (67.8)
Adherence measure type
MPR related 3,058,762 65 26 (46.4)
Discontinuation 1,351,749 28 25 (44.6)
Both 297,782 6.3 5 (9.0)
Number of SES measurements
None 2,961,112 62.9 24 (42.9)
1 1,546,235 32.8 25 (44.6)
41 200,946 4.3 7 (12.5)
If SES was not assessed (N ¼ 24), did study assess ethnicity?
Yes 1,761,764 37.4 5 (8.9)
No 1,199,348 25.5 19 (33.9)
SES measure
One SES measure not related to income
Education 28,395 0.6 1 (1.8)
One SES measure related to income
Prescription drug coverage or medication co-payment amount 1,171,195 24.9 17 (30.4)
Income level 267,379 5.7 4 (7.1)
Social assistance beneﬁts or income security beneﬁts 79,266 1.7 3 (5.4)
More than one SES measure
Two income-related measures 4,525 0.1 2 (3.6)
Three income-related measures 24,443 0.5 1 (1.8)
Income-related measure þ one measure not related to income 104,200 2.2 3 (5.4)
Income-related measure þ two measures not related to income 14,219 0.3 1 (1.8)
Method to measure income
Direct
Link with taxation records 150,609 3.2 3 (5.4)
Indirect
Health plan 53,603 1.1 2 (3.6)
Neighborhood 200,370 4.3 2 (3.6)
Follow-up days category
Up to 180 1,426,148 30.3 13 (23.2)
181–365 2,753,990 58.5 31 (55.4)
4365 502,138 10.7 8 (14.3)
– 26,107 0.6 4 (7.1)
ACEIs, angiotensin-converting enzyme inhibitors; AHT, antihypertensive; ARBs, angiotensin receptor blockers; BBs, beta-blockers; CCBs,
calcium channel blockers; HCTZ, hydrochlorothiazide; MPR, medication possession ratio.
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education [67], living alone [40], or household composition [6].
In total, seven studies captured the income level either
alone or in addition to other SES measures. Of these, classiﬁca-
tion into income groups was obtained directly by linking taxation
data to dispensation records in three studies [6,59,67], indirectly
from census neighborhood income in two studies [40,58],
and indirectly from low-income drug coverage in two studies
[60–65].Nonadherence with Higher SES
Excluding the two studies in which an estimate could not be
obtained [40,41], we extracted data for 40 cohorts in 30 studies
reporting an SES variable. Higher SES was associated with a lower
risk of nonadherence in 31 of 40 cohorts (77.5%), with no differ-
ence in 1 cohort, and with a higher risk of nonadherence in 8
cohorts (Fig. 2). Overall, the pooled adjusted risk estimate indi-
cated a lower risk of nonadherence among individuals with a
higher SES: 0.89 (95% CI 0.87–0.92; P o 0.001); however, high
V A L U E I N H E A L T H 1 7 ( 2 0 1 4 ) 2 8 8 – 2 9 6292heterogeneity was observed (τ ¼ 0.01; I2 ¼ 95%). Inspection of the
funnel plot did not suggest potential publication bias (Fig. 3).
To explore heterogeneity in the results, we performed several
subgroup analyses. Similar results, however, were observed in
studies scoring above 50% on the quality checklist (pooled
adjusted risk estimate 0.90; 95% CI 0.87–0.92; I2 ¼ 95%) and
scoring below 50% (pooled adjusted risk estimate 0.86; 95% CI
0.66–1.12; I2 ¼ 84%). A subgroup analysis was not performed on
measures not related to income because they were identiﬁed only
in one study. Studies that used discontinuation as the end point
(pooled adjusted risk estimate 0.91; 95% CI 0.87–0.96; I2 ¼ 92%)
showed results consistent with those that used MPR-related
measures (0.88; 95% CI 0.85–0.92; I2 ¼ 93%), and studies fromFig. 2 – Pool risk estimates of nonadherence with high socioecon
socioeconomic status.North America and Europe (0.90; 95% CI 0.87–0.94; I2 ¼ 95%)
produced results similar to those from other countries (0.86; 95%
CI 0.81–0.92; I2 ¼ 87%).
In the sensitivity analysis, using the measure with the lowest
effect size (for studies reporting more than one SES variable) did
not change the pooled adjusted risk estimate (0.90; 95% CI 0.88–
0.92; I2 ¼ 95%). Smaller heterogeneity was observed in certain
cohorts restricted by the speciﬁc type of medication used. Pooled
adjusted risk estimates representing the effect of higher SES were
different for cohorts receiving angiotensin-converting enzyme
inhibitors (0.83; 95% CI 0.79–0.88; I2 ¼ 0%), beta-blockers (0.77; 95%
CI 0.66–0.9; I2 ¼ 95%), calcium channel blockers (0.98; 95% CI 0.85–
1.14; I2 ¼ 70%), hydrochlorothiazide (0.81; 95% CI 0.74–0.90;omic status. CI, conﬁdence interval; SE, standard error; SES,
Fig. 3 – Funnel plot of studies identiﬁed in the systematic review. SE, standard error.
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84%), where the test for subgroup difference was signiﬁcant (P o
0.001) (Fig. 4). However, the pooled estimate remained relatively
consistent with the overall ﬁndings.Discussion
Among published studies of nonadherence to AHT medications
using electronic prescription databases, 43% did not account for
any SES measure despite their theorized importance as a deter-
minant of nonadherence [8]. When SES was assessed, the vast
majority of studies identiﬁed single factors relating to income
and none examined SES by using a comprehensive measure.
Pooled analyses indicated that higher SES is associated with an
11% decrease in the adjusted risk of nonadherence; however,
heterogeneity between included studies was very high. Although
the quantitative effect of SES on medication nonadherence
cannot be conﬁrmed from this meta-analysis because of high
levels of heterogeneity, incomplete (or absent) SES measures, and
inconsistent approaches in the literature, these results clearly
demonstrate major deﬁciencies in previous attempts to under-
stand this complex issue. As a result, SES cannot be considered a
strong predictor of medication nonadherence because the evi-
dence supporting this view remains theoretical at best, at least
with respect to AHT medications. In reality, it must be recognized
that current knowledge about SES and nonadherence is
extremely poor.
To our knowledge, this is the ﬁrst systematic review speciﬁ-
cally evaluating the effects of SES on nonadherence to AHT
medications and the results suggest that more research is needed
to ensure a consistent and comprehensive approach to the
assessment of SES as a possible risk indicator. We chose hyper-
tension as a disease state because of its prevalence, chronicity,
lack of symptoms, and treatability [68]. It has been clearly shown
that the prevalence of nonadherence to AHT medications is high
and adverse health outcomes are commonly observed compared
with those demonstrating optimal adherence [69–71]. As a result,
even small improvements in nonadherence are likely considered
clinically meaningful [72–75].
The most probable explanation for these ﬁndings is that
administrative databases including electronic prescriptiondatabases do not have ready access to SES information. The
importance of the SES factors as potential risk indicators of
nonadherence, however, may also be underrecognized. Accord-
ingly, our understanding of the complex relationship between
SES and medication nonadherence is likely incomplete because it
is based on studies using a very limited set of SES measures, at
least in studies focused on AHT medications.
SES could be an important determinant of nonadherence
through its effect on not only affordability and access to medi-
cations but also health literacy and medication knowledge [76].
Indeed, higher SES reduced the risk estimate of nonadherence in
31 of 40 cohorts examined; however, the opposite effect of SES
was observed in 8 of 40 cohorts examined. Thus, our systematic
review conﬁrms and characterizes the inconsistent ﬁndings
relating to SES and nonadherence reported in previous narrative
reviews [11,77,78].
Our review had several limitations. First, our study examined
AHT studies only, and so the results may not generalize to other
chronic disease medications. Second, we included only those
studies that used electronic prescription databases as the source
of nonadherence information. Electronic prescription databases,
however, are the most frequently used source of nonadherence
information among large populations [10]. Third, it is highly likely
that the pooled risk estimates were affected by the lack of
detailed SES information and the inconsistent approaches to
SES measurement in the published literature. Indeed, the vast
majority of SES measures were restricted to income-related
measures. Fourth, we used the checklist developed by ISPOR for
retrospective database studies to assess publications’ quality.
However, a new questionnaire developed by the Academy of
Managed Pharmacy/National Pharmaceutical Council/ISPOR
Comparative Effectiveness Research Collaborative Initiative could
have improved our quality assessment [79]. Last, although we did
not observe any publication bias, it is possible that negative
studies assessing SES and nonadherence could not be published.
SES is frequently overlooked in studies of nonadherence to
AHT medications using electronic prescription databases, and it
has never been examined in a comprehensive way. Based on the
available literature, higher SES appears to be associated with a
small reduction in the occurrence of nonadherence to AHT
medications. This estimate, however, is based on studies that
contained many limitations. Thus, more research is clearly
Fig. 4 – Pool risk estimates of nonadherence with high socioeconomic status, stratiﬁed by medication studied. CI, conﬁdence
interval.
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V A L U E I N H E A L T H 1 7 ( 2 0 1 4 ) 2 8 8 – 2 9 6 295needed to help clarify this relationship. Considering the public
health importance of this outcome and the relative lack of
knowledge about its determinants, failure in taking SES into
account could prevent targeting of interventions for those who
need them.
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